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Summary 
Aim 
To estimate the NHS cost per case of the legal declaratory relief process in relation to withdrawal of 
clinically assisted nutrition and hydration (CANH) from patients diagnosed as being in a permanent 
vegetative state (PVS), in relatively  ?ƐƚƌĂŝŐŚƚĨŽƌǁĂƌĚ ?ĐĂƐĞƐǁŚĞƌĞĨĂŵŝůǇĂŶĚĐůŝŶŝĐŝĂŶƐĂŐƌĞĞƚŚŝƐŝƐŝŶ
the best interests of the patient. 
 
Methods 
The method employed is an incremental cost analysis of declaratory relief compared with no 
declaratory relief, from an NHS cost perspective, including litigation costs borne by the NHS as well 
as ongoing care costs. The comparator is the currently recommended medical decision making 
process prior to application for declaratory relief, including PVS diagnosis by the treating clinician 
following a structured assessment process, confirmation of PVS diagnosis by a medical second 
opinion, ĂŶĚďĞƐƚŝŶƚĞƌĞƐƚĚĞĐŝƐŝŽŶŵĂŬŝŶŐŝŶĐŽŶƐƵůƚĂƚŝŽŶǁŝƚŚƚŚĞƉĂƚŝĞŶƚ ?ƐĨĂŵŝůǇ ? We estimate 
care costs based on a previously validated NHS costing tool for specialised nursing care for patients 
with long-term neurological conditions  ? the  ?Needs and Provision Complexity Scale ?  ? supplemented 
with our own partial  ?micro-costing ? of additional resource use items excluded from this tool, in 
particular costs of medication and feeding, tracheotomy, and hospital  ?blue light ? events. As a check, 
we also perform our own full  ?micro-costing ? of the care costs. We estimate legal costs through 
 ?micro-costing ? of the relevant legal costs borne by the NHS, excluding court infrastructure costs 
falling on the Ministry of Justice rather than the NHS. Our estimates of resource use are based on 
expert opinion; our unit costs are based on published estimates where possible and expert opinion 
where necessary. 
 
Results 
The PVS declaratory relief process lasts, on average, nine months and costs the NHS about £122,000 
per case. This comprises about £53,000 in legal costs and about £69,000 in on-going care costs which 
we estimate cost just over £7,500 per month. We have not included court infrastructure costs in 
these estimates, which fall on the Ministry of Justice rather than the NHS. We estimate that the 
fastest a case can be heard, in the absence of delays, is three months. We estimate that a 
declaratory relief process lasting three months would cost £76,000. 
 
Discussion 
The £122,000 ĐŽƐƚƚŽƚŚĞE,^ŽĨĞĂĐŚ ?ƐƚƌĂŝŐŚƚĨŽƌǁĂƌĚ ?ĚĞĐůĂƌĂƚŽƌǇƌĞůŝ ĨĂƉƉůŝĐĂƚŝŽŶĐĂŶďĞ
expected to displace alternative NHS services and thereby cause a loss of more than 9 quality-
adjusted life years (QALYs) from other NHS patients. This is based on the current best estimate from 
analysis of data on local NHS expenditure and health outcomes, that a reduction of £13,000 in NHS 
expenditure causes a loss of one QALY (Claxton et al. 2013).  
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1. Introduction 
1.1 The declaratory relief (DR) process 
Since the development of the diagnostic category of the  ?ƉĞƌŵĂŶĞŶƚǀĞŐĞƚĂƚŝǀĞƐƚĂƚĞ ? ? ?Ws^ ? ?in the 
early 1970s (Jennet and Plum, 1972), legal systems across the world have had to grapple with the 
question of whether the treatments that sustain the lives of patients in the PVS should be continued 
or terminated. Patients in the vegetative state (VS) have a sleep-wake cycle, and respond to 
stimulation including reflex and spontaneous behaviours, such as grasping and grimacing. However, 
they have no environmental awareness or purposeful movement (Fritz and Bunn, forthcoming). A 
vegetative state lasting more than 4 weeks after a brain injury may be diagnosed as  ?prolonged ?.  
However, patients are not usually diagnosed as permanently in a vegetative state (PVS) until at least 
12 months after a traumatic brain injury and 6 months after a non-traumatic brain injury (Royal 
College of Physicians, 2013).  
 
In some jurisdictions, legal developments have been prompted or informed by high profile and tragic 
cases, England and Wales amongst them. The situation of Anthony Bland, the young football fan 
catastrophically injured in the Hillsborough disaster, ǁĂƐƚŚĞƐƵďũĞĐƚŽĨƚŚĞ,ŽƵƐĞŽĨ>ŽƌĚƐ ?ĨŝƌƐƚ
consideration of an application to withdraw the treatment that was sustaining the life a patient in 
the PVS. In this 1993 case (Airedale NHS Trust v Bland [1993] AC 789), the court established a lasting 
precedent that it is lawful in England and Wales to discontinue the clinically assisted nutrition and 
ŚǇĚƌĂƚŝŽŶ ? ?E, ? ?ŽĨĂƉĂƚŝĞŶƚ in the PVS. According to the legal precedent set in Bland, as soon as a 
patient in an ongoing vegetative state is diagnosed by their treating clinician as being in a permanent 
vegetative state (PVS), ŝƚŝƐŶŽůŽŶŐĞƌůĞŐĂůůǇŝŶƚŚĞƉĂƚŝĞŶƚ ?ƐďĞƐƚŝŶƚĞƌĞƐƚƐƚŽĐŽŶƚŝŶƵĞƌĞĐĞŝǀŝŶŐ
CANH. 
 
In the 20 or so years since the decision in Bland, the legal expectation has been that the court will be 
involved by way of declaratory proceedings in every decision to withdraw CANH from PVS patients, 
even where families and the healthcare team agree that it is an appropriate course of action. The 
House of Lords originally framed this requirement of legal declaratory relief as a matter of good 
practice: 
 
The decision whether or not the continued treatment and care of a P.V.S. patient confers any 
benefit on him is essentially one for the practitioners in charge of his case. The question is 
whether any decision that it does not and that the treatment and care should therefore be 
discontinued should as a matter of routine be brought before the Family Division for 
endorsement or the reverse. The view taken by the President of the Family Division and the 
Court of Appeal was that it should, at least for the time being and until a body of experience 
and practice has been built up which might obviate the need for application in every case. As 
Sir Thomas Bingham M.R. said, this would be in the interests of the protection of patients, the 
protection of doctors, the reassurance of the patients' families and the reassurance of the 
public. I respectfully agree that these considerations render desirable the practice of 
application. (Airedale NHS Trust v Bland [1993] AC 789, at p. 859; emphases added) 
 
However, following the passage of the Mental Capacity Act 2005, the requirement has now become 
a matter of legal obligation, as set out in the Court of Protection Rules (S.I. 2007/1744) and the 2005 
Đƚ ?ƐŽĚĞŽĨWƌĂĐƚŝĐĞ (para 6.18). 
 
1.2 Concerns about the declaratory relief process 
The direct legal supervision of CANH withdrawal decisions in relations to all patients in the PVS, even 
where health care teams and families agree on CANH withdrawal, is unusual in international terms 
(Halliday et al, forthcoming). Existing evidence suggests that most foreign jurisdictions permit 
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withdrawal of CANH from such patients without recourse to the courts. It is also unusual when set 
against the context of wider English medical law. As the British Medical Association has pointed out: 
 
As expertise and professional guidelines develop on PVS, the BMA can see no reason to 
differentiate between decisions for patients in PVS and those for patients with other very 
serious conditions where ANH is not considered to be a benefit, which are currently governed 
by established practice without the need for legal review... The BMA hopes that in future the 
courts will decide that PVS cases no longer inevitably require court review, where consensus 
exists, as long as such withdrawal is in accordance with agreed guidelines. (BMA, 2007: 61)  
 
Equally, the requirement of declaratory relief in these cases also brings economic costs to the NHS, 
in terms both of the necessary litigation costs and the on-going care costs while declaratory relief is 
obtained. These economic costs to the NHS are the subject of this paper. 
 
1.3 Aims of this study 
This study is the first attempt to estimate the costs to the NHS of the declaratory relief process in 
England and Wales for withdrawal of CANH from patients in the PVS. It aims to compare the 
incremental costs per case of the current decision-making model where declaratory relief is a 
requirement, with an alternative model where it is not. It is not viable to estimate the total savings 
to the NHS that abolition of the declaratory relief requirement would bring, as no data exist about 
the prevalence of PVS in England and Wales and it would be difficult to predict the overall effect of 
law reform on the number of cases of CANH withdrawal. There are currently no reliable data on the 
incidence or prevalence of prolonged disorders of consciousness in general, of which vegetative 
state is just one particular case. Prevalence data are likely to be particularly unreliable in relation to 
PVS, since diagnosing a vegetative state as permanent is a highly complex and specialised task that 
carries a grave legal implication  ? i.e. that it is legally not in the best interests of the patient to 
receive CANH. Qualitative data suggest that some families are intimidated or offended by the 
prospect of legal process, and so might become more willing to support withdrawal of CANH in the 
absence of that legal process. Yet, at the same time, other families may become less willing to 
support withdrawal of CANH, insofar as they take reassurance from the court with respect to 
responsibility for the death of their relatives (Halliday et al, forthcoming). Moreover, it is hard to 
estimate the  ?transaction costs ? of legal reform, such as the costs of Parliamentary time and the 
costs of drawing up new legal and NHS guidance. 
 
The primary costing perspective is that of the NHS, including both medical and litigation costs borne 
by the NHS. We do not analyse wider public sector costs borne by the Ministry of Justice in providing 
court infrastructure services, such as general courtroom functioning and judge time. This NHS cost 
perspective is adopted in order to address concern about health opportunity costs in terms of NHS 
resources that could otherwise be used to deliver health services and health benefits to other 
patients. 
 
1.4 Decision-making alternatives compared in the incremental cost analysis 
According to the relevant legal and medical guidelines, the current initial medical stage ought to 
include a thorough medical assessment of the PVS diagnosis, including all relevant assessment 
processes (such as the Wessex Head Injury Matrix [WHIM] and the Sensory Modality and 
Assessment and Rehabilitation Technique [SMART]), and also meetings between family, carers and 
clinicians in order to reach a judgement on the best interests of the patient. In formal terms at least, 
the current decision making process in England and Wales for withdrawal of CANH from an 
individual in the PVS can be divided into two distinct stages.  
 
 
Cost analysis for withdrawing CANH from patients in the PVS  3 
 
First, there should be a medical process in which the treating consultant diagnoses the patient as 
PVS. Accurate diagnosis is a complex process requiring assessment at multiple time points by a 
multi-disciplinary team of experts. Due to the fact that ƚŚĞƉĂƚŝĞŶƚ ?ƐƌĞƐƉŽŶƐĞƐĂƌĞŽĨƚĞŶĚĞůĂǇĞĚ ?
inconsistent and/or confounded by accompanying disabilities, their condition may change, and there 
is always a degree of subjectivity in assessing disorders of consciousness. The diagnostic process 
involves the interpretation of data from a range of sources  ? including medical notes, patient 
observations by family members and care staff at multiple time points, the outcomes of structured 
assessments of the awareness and abilities of vegetative patients  ? such as WHIM and SMART  ? and 
input from multiple disciplines including physiotherapy, occupational therapy, speech and language 
therapy, neuropsychology, nursing and rehabilitation medicine (Royal College of Physicians, 2013: 
14). This diagnosis should then be confirmed by a second senior consultant. The diagnosis implies 
ƚŚĂƚ ?ĨƌŽŵĂůĞŐĂůƉĞƌƐƉĞĐƚŝǀĞ ?ŝƚŝƐŶŽƚŝŶƚŚĞƉĂƚŝĞŶƚ ?Ɛ ?ďĞƐƚŝŶƚĞƌĞƐƚƐ ?ƚŽĐŽŶƚŝŶƵĞE,. It is a legal 
(Mental Capacity Act 2005, s. 4) and good practice requirement (Royal College of Physicians, 2013) 
that decisions ĂďŽƵƚ ?ďĞƐƚŝŶƚĞƌĞƐƚƐ ?are ŵĂĚĞŝŶĐŽŶƐƵůƚĂƚŝŽŶǁŝƚŚƚŚĞƉĂƚŝĞŶƚ ?ƐĨĂŵŝůǇ ? 
 
Second, there must be a legal process whereby the best interests decision must be declared lawful 
by the Court of Protection  ? ƚŚĞƉƌŽĐĞƐƐŽĨŽďƚĂŝŶŝŶŐ ?ĚĞĐůĂƌĂƚŽƌǇƌĞůŝĞĨ ? ?As part of this process, the 
Official Solicitor commissions a third expert opinion to confirm again the diagnosis. This third opinion 
involves a review of all the relevant data (medical notes, the outcomes of the structured assessment 
tools), in addition to discussions with the health care team and family members, and a visit to the 
patient.  
 
Thus, our analysis will compare the incremental cost per case of two different decision making 
models: 
 
a) No Declaratory Relief (NDR)  ? the medical decision making process comprising the PVS 
diagnosis by the treating clinician, the confirmation of the diagnosis by a second 
opinion, and the best interest decision to withdraw CANH made in consultation with the 
ƉĂƚŝĞŶƚ ?ƐĨĂŵŝůǇ ?
 
b) Declaratory Relief (DR)  ? the current two-stage process, comprising the above medical 
decision making process, followed by a second legal process of obtaining declaratory 
relief which involves a third expert opinion and court hearings. 
 
In practice, however, the relevant guidelines are not always followed, and all the appropriate 
medical assessment processes and meetings between family, carers and clinicians are not always 
undertaken prior to the initiation of the declaratory relief proceedings. It is not clear, however, that 
accounting for these empirical realities would substantially change the results. On the one hand, it 
would increase the cost per case of NDR due to undertaking additional tests and meetings that were 
supposed to occur under DR but which in reality do not always occur. On the other hand, we would 
need to allow for the increased legal delays and costs of DR due to medical and legal paperwork not 
being properly prepared in advance of initiating legal proceedings. In the absence of evidence on 
either of these issues, it is not clear which way these two counteracting influences would shift the 
balance of costs. On balance, therefore, we consider our simplified analysis to be approximately 
accurate. 
 
1.5 Related issues not addressed in our analysis 
The focus of our incremental cost analysis is restricted to relatively  ?ƐƚƌĂŝŐŚƚĨŽƌǁĂƌĚ ? PVS cases in 
which both families and the health care team agree that withdrawal of CANH is in the best interests 
of the patient. We do not focus on contested situations where there is disagreement within families, 
or between families and health care teams about the appropriateness of CANH withdrawal, or 
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disagreement amongst clinicians about the PVS diagnosis. Our cost analysis includes declaratory 
relief for the small proportion of patients in the PVS ǁŚŽŚĂǀĞŵĂĚĞĂŶ ?Advanced Decision to 
Refuse Treatment ?(ADRT) under the Mental Capacity Act 2005 to refuse medical treatment in the 
eventuality of being in the PVS. These cases still require declaratory relief to establish that the 
patient is indeed in a permanent vegetative state from which recovery is highly improbable and to 
establish the validity and applicability of the advance directive. However, our analysis does not 
include patients who have conferred a lasting power of attorney (LPOA) under the Mental Capacity 
Act 2005 to make such treatment decisions and where this surrogate decision-maker refuses 
consent to continued CANH. These cases also still require an application to the Court of Protection, 
but the legal process is shorter and so the costs would be substantially lower. 
 
Finally, our analysis does not focus on decision making about patients in a  ?ŵŝŶŝŵĂůůǇĐŽŶƐĐŝŽƵƐ
ƐƚĂƚĞ ?( ?MCS ?), who have intermittent and various levels of awareness of self and environment. In 
contrast to patients in the PVS, the law currently offers little substantive guidance relating to the 
best interests of MCS patients. Whereas the Bland case set a precedent that it is not in the best 
interests of a PVS patient to be maintained in life by CANH, no such precedent exists in relation to 
MCS patients and so each case must be considered on its own merits. In W v M [2011] EWHC 2443, 
for example, it was held that it was in the best interests of that particular patient for her life to be 
maintained through CANH. Yet in United Lincolnshire Hospitals NHS Trust v N [2014] EWCOP 16, the 
Court of Protection declared that it ǁĂƐůĂǁĨƵůĂŶĚŝŶƚŚĞƉĂƌƚŝĐƵůĂƌƉĂƚŝĞŶƚ ?ƐďĞƐƚŝŶƚĞƌĞƐƚƐĨŽƌŚĞƌ
clinicians (a) not to make any further attempt to secure a means of providing artificial nutrition; and 
(b) to withdraw the provision of intravenous fluids. 
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2. Ethical Considerations 
A cost analysis of this nature must be sensitive to the view that there may be areas of medical 
practice where economic analysis should not be undertaken. It may seem unethical to consider the 
financial costs of caring for profoundly vulnerable people, such as PVS patients, since this may seem 
to carry the ethically controversial implication that withdrawal of treatment from vulnerable 
patients can be justified on purely financial grounds. We do not believe our cost analysis carries any 
such implication, for three reasons. First, our analysis focuses on cases in which the family and 
treating clinicians are all in agreement that withdrawal of CANH is in the best interests of the PVS 
patient. Second, our analysis does not aim to inform the patient level decision about whether or not 
to withdraw CANH from a particular PVS patient. Rather, it aims to inform the social level decision 
about the appropriate legal and regulatory framework for making patient level decisions. In 
principle, therefore, this analysis is compatible with the principle that patient level decisions about 
particular PVS patients should be made in the best interests of those patients, and should not 
consider financial costs. Finally, costs falling on cash-limited NHS budgets are not  ?purely ? financial, in 
the sense that they also have a health opportunity cost in terms of NHS services and health benefits 
that could otherwise be delivered to other patients. Ultimately, therefore, financial costs to the NHS 
do translate into human costs  ? albeit human costs borne by unidentified other patients because we 
do not know precisely what other NHS services are foregone or who would have used them. 
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3. Study design 
The method ĞŵƉůŽǇĞĚŝƐƚŚĂƚŽĨĂŶŝŶĐƌĞŵĞŶƚĂů ?ĐŽƐƚĂŶĂůǇƐŝƐ ?ƌĂƚŚĞƌƚŚĂŶ ?ĐŽƐƚ-ďĞŶĞĨŝƚ ? ? ?ĐŽst 
ĞĨĨĞĐƚŝǀĞŶĞƐƐ ?Žƌ ?ĐŽƐƚ-ƵƚŝůŝƚǇ ?ĂŶĂůǇƐŝƐ ? We focus exclusively on costs to the NHS, and do not seek to 
quantify the non-financial benefits and harms to PVS patients and their families. We estimate care 
costs based on standard NHS costings for patients with long-term neurological conditions, 
supplemented with our own partial  ?micro-costing ? of additional resource use including costs of 
CANH and hospital  ?blue light ? events. As a check, we also performed our own full  ?micro-costing ? of 
the care costs  ? that is, we itemised each type of resource use and multiply the volume of resource 
use times an appropriate unit price. We estimate legal costs by micro-costing the relevant legal costs 
borne by the NHS, excluding court infrastructure costs falling on the Ministry of Justice. The list of 
resources and estimates on the quantities of resource use in a  ?typical ? case forms the bedrock of 
our cost analysis.  
 
3.1 Data sources  
For estimating care costs, we drew heavily on previous NHS cost analyses for patients with severe 
and complex neurological disabilities based on the Needs and Provision Complexity Scale (NPCS) 
(Siegert et al. 2012, Turner-Stokes, Bill and Dredge, 2012; Turner-Stokes et al. 2013). The NPCS is a 
tool for measuring the needs of patients with long-term neurological conditions and estimating the 
cost of meeting those needs 
(http://www.kcl.ac.uk/lsm/research/divisions/cicelysaunders/resources/tools/npcs.aspx).  
 
For our own  ?micro-costing ? study we also obtained data on the unit costs of resource use from Unit 
Costs of Health and Social Care 2012 (Curtis 2012). We also reviewed the judgments of all PVS cases 
that have gone before the Court of Protection, to help estimate the typical duration of such cases 
and gather information on the nature of the process. Where no evidence is available, we have also 
made assumptions about particular cost parameters based on information from the recently 
published Royal College of Physicians best practice guidance for patients with prolonged disorders of 
consciousness (Royal College of Physicians 2013) and consultation with medical specialists with 
experience of the declaratory relief process. These specialists include two neurologists with 
experience as expert witnesses in PVS cases held at the Court of Protection. 
 
Published information on resource use and unit costs of legal representation and medical expert 
witnesses were not available, so we made assumptions following consultation with consultants, 
barristers and solicitors who have been involved in several PVS cases of declaratory relief. We also 
took Court of Protection fees from the HM Courts and Tribunals Service website at 
http://hmctsformfinder.justice.gov.uk/courtfinder/forms/cop044-eng.pdf 
 
3.2 Key assumptions 
Several key assumptions underpin our economic analysis. The first is that the NHS funds the 
application for declaratory relief. A review of relevant case law reveals that this is usually (though 
not always) the case. TŚĞƐĞĐŽŶĚŬĞǇĂƐƐƵŵƉƚŝŽŶƌĞůĂƚĞƐƚŽƚŚĞĚĞůĂǇďĞƚǁĞĞŶĂ ?ďĞƐƚŝŶƚĞƌĞƐƚƐ ?
decision to withdraw CANH from a PVS patient and the declaration of that ĚĞĐŝƐŝŽŶ ?ƐůĂǁĨƵůŶĞƐƐ ? 
Clearly, the actual time taken varies between cases. Only a few of the published judgments detail 
the timelines involved. Our costs analysis assumes that, on average, the delay is 9 months. This 
assumption derives from discussions with clinicians and lawyers who have considerable experience 
of the declaratory relief process. A recent study found that the average delay may be longer than 
this in other kinds of cases heard by the Court of Protection 
(http://sites.cardiff.ac.uk/wccop/files/2015/01/Local-Authorities-Use-of-the-CoP.pdf). However, we 
believe our estimate of 9 months is a more appropriate and conservative estimate for PVS cases of 
this highly specific kind. 
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The third key assumption is that, although patients in the early stages of their disorders of 
consciousness are likely to spend time in specialist hospital rehabilitation units, the vast majority 
(95%) of patients in a permanent vegetative state are cared for in nursing homes, with only a small 
proportion being cared for in family homes (5%). This assumption derives from discussions with 
experienced clinicians. 
 
The fourth assumption is that legal costs are all  ?fixed costs ? that do not vary with the duration of the 
DR process.  
 
Lastly, we assume that only two court hearings take place: one preliminary directions hearing and a 
final hearing. 
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4. Results 
Figure 1 presents our estimates of the average legal and ongoing care cost to the NHS of the 
declaratory relief (DR) process. Medical care costs increase with time duration, whereas legal costs 
are fixed. Using our assumption of 9 months for the time taken between a best interests decision to 
withdraw CANH and the declaration of lawfulness, we estimate the average additional costs of the 
DR process to be about £122,000, comprising about £53,000 in fixed legal costs and about £69,000 
in ongoing care costs. We have rounded these figures to the nearest thousand, to avoid giving an 
impression of spurious accuracy. 
Figure 1: Total NHS costs of the DR process (£000s), including both legal costs and ongoing care costs 
Note to Figure 1 
1. We assume the DR process on average takes 9 months. 
 
4.1 Ongoing care costs 
Most PVS patients are cared for in specialised nursing homes, but a few are cared for in private 
family homes. These different care settings have slightly different costs, so to estimate an average 
cost for a  ?typical ? PVS patient we need to estimate the proportion of PVS patients treated in these 
different settings. As noted above, we have estimated that:  
 
x 95% of PVS patients are in specialised nursing homes 
x 5% of PVS patients are cared for at home 
 
We assume that no PVS patients are cared for in hospital rehabilitation units. Patients are often 
treated in such units at early stages of their disorder of consciousness, but not at the later stages 
that we are considering here. Nonetheless, for completeness, we also provide estimates of the cost 
of care in hospital rehabilitation units below, to put the other cost estimates into context. The costs 
below are averages; as with any other form of health care there are of course substantial variations 
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in cost between individual patients due to variation in individual needs and in local provider unit 
prices and patterns of care. 
 
Specialised Nursing Home: The basic average annual cost of a PVS patient in a specialised 
nursing home has been ascertained through NPCS costing computations as £71,656 (Siegert et 
al. 2013; costing algorithm page 8). However, we need to add to this a further annual cost of 
percutaneous endoscopic gastrostomy (PEG) feed and medication costs of £8,213 per year, 
plus tracheotomy costs of £5,200, bringing the total annual cost to £85,069. This is based on 
an expert assumption that the costs of medication and PEG amounts to £20-£25 per day; from 
which we have taken an average of £23 per day, and that 50% of patients require 
tracheotomy which costs about £200 a week. 
 
At home: To ascertain the costs of care of a typical PVS patient at home, we examined patient 
level data on need level and cost based on the NPCS costing tool. We examined data on 8 PVS 
patients obtained from a specialised NHS trust in London, and found that the median PVS 
patient had an average annual cost of £116,012 over a year based on a Northwick Park 
Dependency Scale (NPDS) need level of 46. As a check on these estimates, we also examined 
data on 33 MCS patients and found they had similar need levels and costs, as would be 
expected. The family will bear additional out-of-pocket costs themselves, but in this study we 
are focusing on costs to the NHS only. 
 
Hospital Rehabilitation Unit: A regional level hospital rehabilitation unit is the most intensive 
form of care available to a PVS patient. Turner Stokes and colleagues place an annual cost of a 
PVS patient in this context at £193,450 based on a cost per day of £530, or £146,730 in a local 
district level unit based on a cost per day of £402 (Turner-Stokes, Bill and Dredge, 2012). 
 
dŽƚŚĞƐĞĐŽƐƚƐǁĞŚĂǀĞĂůƐŽĂĚĚĞĚĐŽƐƚƐƚŽƚŚĞE,^ŽĨ ?ďůƵĞůŝŐŚƚĞǀĞŶƚƐ ?that result in a visit to 
hospital, such as pneumonia and urinary tract infections. These costs were based on expert opinion 
of one event per year (12 months) and that 1 episode would last 10 days, with a hospital treatment 
cost of £500 per day based on NHS Reference Costs (Department of Health, 2013). This then 
becomes an additional one off cost of £5,000. 
 
Table 1 shows the medical cost of care in different settings for different durations (a year, a month 
and a day). The weighted averages can be interpreted as the average cost of care for a  ?typical ? PVS 
patient, with weights reflecting the estimated proportion of patients in each setting. The medical 
cost of a  ?typical ? PVS patient in England and Wales is £86,676 per year. We then add the cost of 
ŚŽƐƉŝƚĂů ?ďůƵĞůŝŐŚƚ ?ĞǀĞŶƚƐ ?ŽŶƚŚĞĂƐƐƵŵƉƚŝŽŶƚŚĂƚŽŶĂǀĞƌĂŐĞĂůůƉĂƚŝĞŶƚƐ have one such event per 
year, bringing the total annual cost to £91,616. 
 
Table 1: Ongoing PVS Care Costs Per Year, Month and Day (2011 figures)  
 Cost Per Year Cost Per 
Month 
Cost Per 
Day 
Weight 
(Proportion 
of Patients) 
1. Specialist nursing home 85,069 7,089 233 0.95 
2. At home 116,012 9,668 318 0.05 
3. Weighted average of 1 and 2 86,616 7,218 237  
4. Hospital 'blue light' events 5,000 417 14  
Total cost (3 + 4) 91,616 7,635 251  
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Finally, as a robustness check and to help understand the individual components of the cost of care, 
we also performed our own independent  ?micro-costing ? of the costs of care for a PVS patient 
treated at home (details available from the authors on request). By far the largest element of cost is 
the cost of care assistant staff to provide continuous round-the-clock care, which comprises just over 
80% of the cost. The average cost per year from this analysis was £122,683 which is 5% more than 
the NPCS based estimate of £116,012. However, we use the costs from the NPCS tool, as this official 
NHS costing tool is based on a more thoroughly validated set of underpinning resource use and unit 
cost estimates and hence is likely to be more accurate than our own estimate. 
 
4.2 Legal costs 
We focus on the out-of-pocket legal fees paid by the applicant, which is usually the NHS. We exclude 
legal infrastructure costs borne by the Court of Protection and the Ministry of Justice, such as 
staffing and facilities costs for judges and other court officials. We assume the legal DR process in a 
relatively  ?straightforward ? case involves two hearings: a preliminary directions hearing and a final 
hearing. In some cases things may initially seem straightforward but then later become contested, 
for example if the consultant acting for the official solicitor raises unexpected concerns about the 
PVS diagnosis requiring further medical assessment and a third hearing. Since this only happens in a 
small proportion of cases, however, this would not substantially increase our average cost estimates 
and so to keep things simple and conservative we do not explicitly cost out this scenario. 
 
Table 2 shows the total legal costs of the declaratory relief process to the NHS. The largest item of 
legal cost to the NHS, making up more than 80% of the cost, is the legal representation fees. This 
includes 100% of the fees for the barristers and solicitors acting for the applicant (usually an NHS 
body) and by convention the NHS also pays 50% of the fees for the barristers and solicitors acting for 
the Official Solicitor  ?ĂĐƚŝŶŐĂƐƚŚĞ ?ůŝƚŝŐĂƚŝŽŶĨƌŝĞŶĚ ?ŽĨƚŚĞƉĂƚŝĞŶƚ ?. The solicitors ? fees include pre-
meetings and preparation, instruction of experts and counsel, writing and responding to 
correspondence, and preparing the application, as well as attending both hearings. 
 
The second largest cost driver is the cost of medical staff time in preparing their medical expert 
witness reports and, in the case of the third opinion, attending court. We assume that the court 
requires three written medical witness reports, from (1) the treating consultant, (2) a senior 
consultant providing a second opinion, and (3) a senior consultant acting for the Official Solicitor to 
provide a  ?third opinion ?.  Conservatively, we also assume that only one medical witness is required 
to attend the hearing to give verbal evidence. We estimate that each report requires 9 hours of 
consultant time, including reading through the bundle of documentation (usually 4 or 5 lever arch 
files), interviewing staff and family members, and examining the patient, plus further time to write a 
detailed report. This includes an allowance for travelling, administration and the possibility that 
report writing takes longer than expected; all of which will depend upon the distances travelled and 
the complexity of the case, including how far the witness is coming in  ?cold ? or is already familiar 
with the case. We estimate that attending court requires 12 hours of senior consultant time, 
including pre-meetings to prepare for the hearing as well as travel and administration, and a small 
additional time allowance for the risk that further hearings are required or that more than one 
medical witness is required to attend. Conservatively, we cost consultant time at NHS service rates 
of £155 per hour for the treating consultant and £195 for the senior consultants, rather than at 
higher commercial rates. This is because our focus is on the opportunity cost to the NHS in terms of 
consultant time taken away from other NHS activities. We do not include the cost of a full de novo 
assessment of the PVS diagnosis, such as a SMART assessment, since we assume this has already 
been undertaken during the medical best interests decision making process prior to the legal DR 
process being initiated. 
 
Finally, we have included standard Court of Protection fees of £900, payable by the applicant. 
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Table 2: Legal costs to the NHS of the DR process 
General cost category Sub-category 
Cost 
£ % Total 
A. Legal Representation costs Total 45,000 85 
  
Plaintiff barrister's fee 15,000 28 
Plaintiff solicitor's fee 15,000 28 
50% of barrister's fee for Official Solicitor 7,500 14 
50% of solicitor's fee for Official Solicitor 7,500 14 
B. Medical witness costs Total 7,245 14 
  
Treating consultant report 1,395 3 
Second opinion report 1,755 3 
Third opinion report (Official Solicitor) 1,755 3 
One witness prepare and attend court 2,340 4 
C. Court of Protection costs Total 900 2 
  
Application fee 400 1 
Hearing fee 500 1 
Total   53,145 100 
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5. Discussion 
We have estimated that the declaratory relief process lasts, on average, nine months and costs the 
NHS about £122,000 per case, comprising about £53,000 in fixed legal costs and about £69,000 in 
ongoing care costs which we estimate on average cost £7,635 per month or £251 per day. We have 
not included court infrastructure costs in these estimates, such as the cost of courtroom facilities 
and judge time, which fall on the Ministry of Justice rather than the NHS.  
 
There is a degree of uncertainty around this average cost estimate. One source of uncertainty is 
variation in the unit cost of care in different institutions and the fees charged by different barristers 
and solicitors. However, the main source of uncertainty is the duration of the average case. Our 
estimate of nine months is based on review of the duration of past cases and discussions with 
barristers and consultants involved in past cases. From these discussions, the main sources of delay 
appeared to be the scheduling of dates for hearings and the time taken for the medical third opinion 
to complete their assessment on behalf of the official solicitor, in the context of a national shortage 
of experienced medical consultants capable of undertaking this specialised and time-consuming task. 
In the absence of these delays, we estimate that the fastest a case could realistically be processed is 
three months. If so, that would imply a cost of £76,000 comprising the same £53,000 in fixed legal 
costs and about £23,000 in ongoing care costs for the three month period. 
 
From a national perspective, the potential total savings from abolishing the declaratory relief 
requirement in relatively  ?straightforward ? cases where clinicians and families agree about 
withdrawal of CANH are very small. Although we do not know exactly how many of such cases have 
come before the Court of Protection, it has recently been estimated that there has been a little more 
than 100 cases in the 20 years or so since the Bland case (Kitzinger and Kitzinger, 2015). Some of 
these cases have involved disputes between families and clinicians, or disagreements about 
diagnosis. The number of uncontested cases reaching court every year is therefore fairly low, and 
the total savings to the NHS would be vanishingly small relative to its annual budget, which in 
2012/2013 was £105 billion (NHS Confederation 2014). 
 
Nevertheless, each case of legal declaratory relief in the relatively  ?ƐƚƌĂŝŐŚƚĨŽƌǁĂƌĚ ?ĐĂƐĞƐŽŶǁŚŝĐŚ
we focus clearly imposes a non-negligible opportunity cost on the NHS in terms of other beneficial 
NHS services that could have been provided using those resources. The NHS exists for the benefit of 
patients. Costs to the NHS are, ultimately, human costs to individual patients in terms of their health 
care. It may be appropriate, then, to frame the costs of the declaratory relief process in terms of the 
standard metric of health benefit that the NHS uses to assess such opportunity costs  ? the quality-
ĂĚũƵƐƚĞĚůŝĨĞǇĞĂƌ ? ?Y>z ? ?, which represents a year of life in full health. The best available evidence 
suggests that, on average, every £13,000 (approximately) of reduction in NHS expenditure causes 
the loss of one QALY (Claxton et al, 2013). This estimate is based on econometric analysis of data on 
local NHS expenditure and health outcomes. Based on this estimate, we can estimate that each 
declaratory relief application (in straightforward cases) takes over 9 years of life (quality-adjusted) 
from other patients. The calculation is simple: the cost of £122,000 is divided by the cost per QALY 
value of £13,000 to yield 9.4 QALYs foregone. 
 
Alternative ways of translating between financial costs and QALY outcomes, based on different 
conceptual foundations, generally yield higher cost per QALY values. First, the officially declared 
National Institute for Health and Care Excellence (NICE) threshold value for considering a technology 
to be cost-effective is £20,000 per QALY (NICE 2013). Second, analysis of past NICE decisions 
suggests that the  ?revealed ? threshold value of a QALY applied by NICE is more like £40,000 per QALY 
(Dakin et al. 2014). Third, the consumption value of a QALY used by the Department of Health to 
value health benefits when appraising  ?inter-sectoral ? public policies with costs falling outside the 
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NHS budget is £60,000 per QALY (Glover and Henderson 2010, para 5.21). This third approach is not 
appropriate in our case, since we are only assessing the costs of declaratory relief that do fall on NHS 
budgets. The cost per QALY values associated with NICE could be considered appropriate if the idea 
were to apply the same cost-effectiveness test to declaratory relief as is applied by NICE to other 
forms of NHS activity. Using the  ?official ? NICE threshold value of £20,000 implies that each 
declaratory relief decision would need to deliver a health benefit of 6.1 years of life in full health in 
order to be considered cost-effective by NICE. Alternatively, using the  ?revealed ? threshold value of 
£40,000 implies that each declaratory relief decision would need to deliver a health benefit of 3.1 
years of life in full health in order to be considered cost-effective. We do not attempt to perform a 
cost-effectiveness analysis, however, as the appropriate  ?quality adjustment ? to apply to gains and 
losses of life in a PVS health state is controversial and data on public views are limited. 
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